Please note that the ANZCTR website will be unavailable from 9am until 9.30am (AEST) on Monday 22nd July for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00504907




Registration number
NCT00504907
Ethics application status
Date submitted
18/07/2007
Date registered
20/07/2007
Date last updated
30/05/2018

Titles & IDs
Public title
Safety Study of Oral BTA9881 to Treat RSV Infection
Scientific title
A Phase I, Single-Centre, Double-Blind, Placebo-Controlled, Escalating Single Oral Dose, Safety and Tolerability Clinical Trial With BTA9881 in Healthy Subjects
Secondary ID [1] 0 0
BTA9881-01
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Virus Infections 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BTA9881
Treatment: Drugs - Placebo

Experimental: Cohort A - Placebo or BTA9881 -10mg

Experimental: Cohort B - Placebo or BTA9881 - 10mg

Experimental: Cohort C - Placebo or BTA9881 - 25mg

Experimental: Cohort D - Placebo or BTA9881 - 50mg

Experimental: Cohort E - Placebo or BTA9881 - 100mg

Experimental: Cohort F - Placebo or BTA9881 - 200mg

Experimental: Cohort G - Placebo or BTA9881 - 400mg


Treatment: Drugs: BTA9881
Single oral escalating doses

Treatment: Drugs: Placebo


Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To evaluate the safety and tolerability of ascending single oral doses of BTA9881 in healthy adult subjects.
Timepoint [1] 0 0
Two weeks
Secondary outcome [1] 0 0
To assess the pharmacokinetics and dose proportionality of BTA9881 after a single oral dose in healthy adult subjects
Timepoint [1] 0 0
Two weeks

Eligibility
Key inclusion criteria
1. Healthy male and female subjects >=18 and <=45 years of age.

2. Individuals who have freely given Informed Consent in writing.

3. Male subjects should use appropriate contraception (e.g. condoms) during the time
interval between dosing until three months after dosing. Female subjects must be
surgically sterile or post-menopausal (defined as at least two years post cessation of
menses and/or follicle-stimulating hormone (FSH) >18 mIU/mL and serum oestradiol <110
pmol/L), or must agree to use two forms of the following contraception: oral
contraceptives, or other forms of hormonal birth control including hormonal vaginal
rings or transdermal patches, intra-uterine devices, condoms, and spermicide during
the time interval between dosing until three months after dosing. Female subjects must
also be non-lactating and have a negative serum pregnancy test at screening and at
baseline.

4. Able to perform nasal wash procedure.

5. Normotensive (systolic BP = 140 mm Hg and diastolic BP = 90 mm Hg).

6. No abnormal finding of clinical relevance at the screening examination that the
Investigator considers might interfere with the objectives of this clinical trial.

7. No clinically relevant abnormality in the ECG; QTc <430 ms (males) or <450 ms
(females).

8. Healthy based on medical history, physical examination, 12-lead ECG and clinical
laboratory tests, and with no disease that the Investigator regards as clinically
relevant.

9. Negative results in Human Immunodeficiency Virus (HIV) antibody, Hepatitis B surface
antigen (HBsAg) and Hepatitis C antibody tests.

10. Willingness to abstain from alcohol and caffeine-containing food and beverages for 48
hours prior to dosing and for the duration of the clinical trial.
Minimum age
18 Years
Maximum age
45 Years
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Use of any prescription medication (other than allowable oral contraceptives and
implanted hormonal contraceptives) during the 14 days prior to dosing.

2. Use of any non-prescription ('over the counter') product, including herbal products,
diet aids, hormone supplements, etc., within 14 days prior to dosing.

3. Intake of any investigational drug within 3 months prior to dosing.

4. History or clinical evidence of significant cardiovascular disease (including risk
factors for cardiac arrhythmias) or a previous history of any cardiovascular condition
that, in the opinion of the investigator, would interfere with the conduct of the
trial.

5. History or clinical evidence of significant cerebrovascular, cardiovascular,
gastrointestinal, or haematological disease, or myocardial infarction, or a previous
history of any other serious underlying disease (including immunocompromised subjects
and/or neutropenic subjects) that, in the opinion of the investigator would interfere
with the conduct of the clinical trial.

6. History or clinical evidence of significant respiratory disease (including asthma,
chronic obstructive pulmonary disease, cystic fibrosis and/or recurrent lower
respiratory tract infection), or upper respiratory tract infection within the last
month or lower respiratory tract infection within the last three months.

7. History or clinical evidence of renal disease (including renovascular occlusive
disease), nephrectomy and/or renal transplant, and/or previous clinically significant
laboratory abnormalities of renal function parameters. All subjects with serum
creatinine or proteinuria outside the normal laboratory reference range at screening
and baseline that are regarded by the Investigator as clinically significant.

8. History or clinical evidence of hepatic disease and/or previous clinically significant
laboratory abnormalities of liver function parameters. All subjects with bilirubin,
gamma glutamyl transferase (GGT), alanine transaminase (ALT), and aspartate
transaminase (AST) outside the normal laboratory reference range at screening and
baseline, that are regarded by the Investigator as clinically significant. Subjects
known to have experienced elevated liver enzyme values in previous clinical studies
will also be excluded.

9. History or clinical evidence of adrenal disease (including Cushing's Syndrome or
Addison's disease) or thyroid disease (including hyper or hypothyroidism), and/or
previous clinically significant laboratory abnormalities of adrenal or thyroid
function parameters. All subjects with thyroid function (TSH, FT4, FT3) outside the
normal laboratory reference range at baseline and regarded by the Investigator as
clinically significant.

10. Psychiatric or emotional problems that would invalidate the giving of Informed Consent
or limit the ability of the subject to comply with clinical trial requirements.

11. Body Mass Index (BMI) =18.5 kg/m2 or >=30.0 kg/m2.

12. History of alcohol and/or drug abuse within 1 year prior to screening (verified by
drug screening).

13. Receipt of blood or blood products, or loss of 450 mL or more of blood, during the
last three months prior to dosing.

14. Unwillingness or inability to provide Informed Consent or to participate
satisfactorily for the entire clinical trial period.

15. Subjects who smoke or have been non-smokers for less than 3 months prior to dosing.

16. Subjects who were previously enrolled in this clinical trial.

17. Poor veins, or fear of venipuncture or sight of blood, or known allergy or
hypersensitivity to lidocaine.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Nucleus Network - Melbourne
Recruitment postcode(s) [1] 0 0
3004 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Biota Scientific Management Pty Ltd
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a placebo-controlled, double-blind, randomised, single dose escalation Phase I
clinical trial to determine the safety and tolerability of BTA9881 administered orally to
healthy subjects
Trial website
https://clinicaltrials.gov/show/NCT00504907
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Peter Hodsman, MD
Address 0 0
Nucleus Network
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications